Pax-1 Activators
Pax-1 activators encompass a diverse array of chemical compounds that indirectly enhance the transcription factor's role in gene expression regulation, particularly during embryonic development. Retinoic Acid is one such molecule, which by participating in retinoid signaling, can modulate the embryonic cellular context, potentially increasing the accessibility of Pax-1 target genes. Similarly,Forskolin and Epigallocatechin gallate (EGCG) act through the elevation of cAMP and inhibition of kinases, respectively, creating an environment that may favor Pax-1's interactions with co-factors and DNA-binding sites. Sodium Butyrate and Trichostatin A, both histone deacetylase inhibitors, enhance the chromatin's open state, which may facilitate Pax-1's access to DNA and enhance its transcriptional activity. Compounds like 5-Azacytidine and LY294002, which affect DNA methylation and PI3K/AKT signaling pathways, respectively, can create a cellular milieu conducive to Pax-1 activity by modifying the epigenetic landscape and phosphorylation patterns of proteins that interact with Pax-1. Dorsomorphin and SB431542 modulate developmental signaling pathways such as BMP and TGF-β, potentially affecting Pax-1's expression and functional engagement with developmental processes.
The activity of Pax-1 is further influenced by compounds that affect cellular signaling and architecture. PD0325901, a MEK inhibitor, may enhance Pax-1's function by influencing the MAPK/ERK pathway, which plays a critical role in cell differentiation, a process where Pax-1 is a known regulator. Y-27632, a ROCK inhibitor, by altering cytoskeletal dynamics, might indirectly impact Pax-1's role in the cellular framework, while BIO, a GSK-3 inhibitor, by stabilizing β-catenin levels, could influence Wnt signaling pathways that are crucial for the processes Pax-1 regulates. These activators, through their targeted biochemical mechanisms, support the enhancement of Pax-1-mediated functions by influencing the intricate network of signaling pathways that govern cellular development and differentiation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid influences the retinoic acid signaling pathway. Pax-1 is expressed during development and can be influenced by retinoid signaling, which regulates gene expression during embryonic morphogenesis. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylyl cyclase, increasing cAMP levels, which can lead to activation of PKA. PKA may impact the phosphorylation state of factors that cooperate with Pax-1, thereby enhancing its functional activity in gene expression regulation. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
Epigallocatechin Gallate is known to act as a kinase inhibitor. By inhibiting certain kinases, EGCG could indirectly enhance Pax-1 activity by reducing inhibitory phosphorylation on proteins that interact with or regulate Pax-1. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
Sodium butyrate is a histone deacetylase inhibitor that leads to a more relaxed chromatin structure, potentially facilitating the access of Pax-1 to its DNA-binding sites and enhancing its transcriptional activity. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine, a DNA methyltransferase inhibitor, can lead to demethylation of gene promoter regions. Hypomethylated states can increase the accessibility of transcription factors like Pax-1 to their target genes. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is also a histone deacetylase inhibitor, enhancing chromatin accessibility. This can increase Pax-1 interaction with target gene promoters, potentially enhancing its functional activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, which can alter AKT signaling. Changes in the AKT pathway may affect the cellular context in which Pax-1 operates, potentially enhancing its activity by altering the phosphorylation state of interacting proteins. | ||||||
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $96.00 $355.00 | 69 | |
BML-275 (Dorsomorphin) inhibits BMP signaling by targeting the BMP type I receptors ALK2, ALK3, and ALK6. Since Pax-1 is expressed in the developing somite, influenced by BMP signaling, this inhibitor may indirectly enhance Pax-1 activity by affecting somitogenesis and Pax-1 expression patterns. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542 selectively inhibits ALK4, ALK5, and ALK7, which are TGF-β type I receptors. By modulating TGF-β signaling, which is involved in development, this could indirectly increase Pax-1 activity by altering the cellular environment that affects Pax-1 function. | ||||||